Julien Bradley Joins CellChorus as Advisor

·2 min read

HOUSTON, May 17, 2022--(BUSINESS WIRE)--CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how thousands of individual cells perform and interact over time, announced the addition of Julien Bradley, CEO of RedShift BioAnalytics, as a member of its advisory board.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005078/en/

Julien Bradley, CEO of RedShift BioAnalytics, has joined the CellChorus advisory board. (© Julien Bradley)

"CellChorus is advancing the next frontier of single-cell analysis for the life sciences industry," said Daniel Meyer, CEO of CellChorus. "I have known Julien for more than 15 years. He is a person who shares our values and has dedicated his career to advancing the development and delivery of novel therapies for patients. We are fortunate to benefit from his wealth of experience in developing and commercializing life sciences technologies from his leadership roles at RedShift BioAnalytics, Quanterix, Thermo Fisher Scientific, and Ahura Scientific."

Mr. Bradley is the Chief Executive Officer of RedShift BioAnalytics, a venture-backed company that offers a novel platform for measuring previously undetectable structural changes in biomolecules. Prior to joining RedShiftBio, he held a variety of executive leadership roles at Quanterix in sales, marketing, corporate development and strategy. Mr. Bradley holds an MBA from the Tuck School of Business at Dartmouth and a BA in Biology from Amherst College.

"The life sciences industry has been revolutionized by single cell analysis in genomics, transcriptomics and proteomics," said Mr. Bradley. "But there has remained a gap in understanding how individual immune cells actually perform and fight disease in indications such as oncology and infection diseases. I am pleased to be able to support the important work that the CellChorus team is doing to improve the development and delivery of novel therapies to improve the lives of patients."

About CellChorus

CellChorus is the leader in applying artificial intelligence to visually evaluate how thousands of individual cells, such as T cells and NK cells, perform over time. The company applies Time‑lapse Imaging Microscopy in Nanowell Grids (TIMING™) with neural network-based detection to identify cells and evaluate their activity, including how they move, activate, kill and survive. The patent‑protected CellChorus platform links TIMING data and insight with information from other analysis modalities such as single‑cell RNA sequencing and flow cytometry to provide a comprehensive understanding of cellular function, state and phenotype for the life sciences industry. Please visit cellchorus.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005078/en/


Daniel Meyer
Chief Executive Officer
CellChorus Inc.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting